Market Access News | pharmaphorum

News

Study prompts call for ‘30th birthday’ screening tests

Routine screening at 30 for three genetic conditions that predispose to cancer and cardiovascular disease could save health services money, according to a recently publish

News

CDC panel backs use of GSK, Pfizer’s RSV shots this year

Adults aged 60 and over in the US will be eligible for vaccinations with respiratory syncytial virus (RSV) vaccines from GSK or Pfizer later this year, if the Centers for

News

Pfizer joins three-way PARP battle in prostate cancer

Pfizer has won FDA approval for its PARP inhibitor Talzenna in castration-resistant prostate cancer (CRPC) in a combination that it hopes will help it challenge AstraZenec

News

Argenx gets FDA nod for first subcutaneous gMG therapy

The market for drugs to treat the muscle-wasting disease generalised myasthenia gravis (gMG) is getting more crowded, and Argenx has just claimed an FDA approval that coul

News

Alarm bell rung over EU’s unified HTA plan

The EU’s joint clinical assessment (JCA) initiative has been set up to accelerate patient access to new therapies, but could end up restricting the use of new technologies

News

Catalyst throws lifeline to Santhera with $90m Duchenne deal

Swiss biotech Santhera has found a North American partner for its Duchenne muscular dystrophy (DMD) therapy vamorolone, ahead of an FDA decision on the drug due by 26th Oc

Study prompts call for ‘30th birthday’ screening tests

CDC panel backs use of GSK, Pfizer’s RSV shots this year

Pfizer joins three-way PARP battle in prostate cancer

Argenx gets FDA nod for first subcutaneous gMG therapy

Alarm bell rung over EU’s unified HTA plan

Catalyst throws lifeline to Santhera with $90m Duchenne deal

UK seeks views on indefinite CE marks for medical devices

How to meet your physicians where they are online

News

Editor's Picks